Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.

Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial. The move marks a setback for a

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of

The investor Venrock will make $900 million on a relatively small $20 million investment into Kelonia Therapeutics, which on Monday agreed to sell itself to